Drugs / TQB3804
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04128085 | Nov 2019 → Oct 2020 | cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3804 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04128085 ↗ |
| Route | Oral | “TQB3804 tablet administered orally” NCT04128085 ↗ |